Target intelligence / Profile preview

Synaptotagmin-1 and Synaptotagmin-2 (Syt1 and Syt2)

Target
Syt1 and Syt2
Molecular classification
Other (Synaptic vesicle membrane protein), Calcium sensor, Vesicle trafficking protein
01

Overview

Synaptotagmin-1 and Synaptotagmin-2 are integral membrane proteins of synaptic vesicles in neurons, functioning as principal calcium sensors that trigger rapid, synchronous neurotransmitter release at synapses, particularly at neuromuscular junctions and other fast-conducting synapses in the central and peripheral nervous systems[1][3][4]. Both isoforms share a conserved structure with two C2 calcium-binding domains and play partially overlapping but distinct roles: Synaptotagmin-1 predominates in the central nervous system and immature nerve terminals, while Synaptotagmin-2 is particularly abundant in mature motor neuron terminals at neuromuscular junctions and selected brain regions. Deletion or dysfunction of Synaptotagmin-2 causes severe and often lethal impairment of synaptic transmission and motor function, highlighting their essential role in neuronal communication[1][5]. Synaptotagmin-1, together with Synaptotagmin-2, enables precise timing of neurotransmitter release in response to calcium influx, a process critical for muscle contraction and normal motor behavior[1][2][4][5].

Other names
Synaptotagmin ISynaptotagmin IISyt ISyt IISYT1SYT2Ca2+ sensor for fast neurotransmitter release
02

Mechanism of action

Drugs/toxins affecting the SNARE complex or disrupting calcium-triggered neurotransmitter release would functionally affect synaptotagmin-1 and -2

03

Biological functions

Regulation of fast synaptic vesicle exocytosisCalcium-triggered neurotransmitter releaseSynapse formation and maturation
04

Disease associations

Neurodegenerative diseaseMotor dysfunction disordersPotential role in neuromuscular diseases and selected forms of Parkinson’s disease
05

Safety considerations

Severe impairment of synaptic transmission when dysfunctional, including lethal motor dysfunction if deleted in animal modelsNo known contraindications with direct targeting, but loss-of-function is associated with profound physiological deficits
06

Biomarkers

Loss or mutation may act as a research biomarker for impaired neurotransmitter release at motor synapses and neuromuscular junctions

Beyond the preview

Go deeper on Synaptotagmin-1 and Synaptotagmin-2 (Syt1 and Syt2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synaptotagmin-1 and Synaptotagmin-2 (Syt1 and Syt2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call